Summary: Skye Bioscience Inc, a clinical-stage biopharmaceutical company, reported its second-quarter results, emphasizing the upcoming phase 2 trial of nimacimab, a treatment for obesity that will also explore the impact of weight loss on sleep quality using Beacon Biosignal’s … [Read more...]
Incannex Sleep Apnea Drug Trial: Key Findings
Summary: Incannex Healthcare has completed dosing in a clinical trial evaluating the bioavailability and bioequivalence of IHL-42X, a combination drug candidate for treating obstructive sleep apnea. The trial compared the bioavailability of IHL-42X’s components, dronabinol and … [Read more...]
Sleep Monitoring Integrated into Phase 2 Obesity Drug Trial
Summary: Beacon Biosignals and Skye Bioscience are partnering to integrate sleep quality and sleep apnea endpoints in a phase 2 trial of obesity drug candidate Nimacimab. The trial will utilize sleep monitoring technology to provide an assessment of the drug’s impact on … [Read more...]
Apnimed Completes Enrollment for Phase 3 Sleep Apnea Drug Trial
Summary: Apnimed, a medical-stage pharmaceutical enterprise, has done early enrollment for its LunAIRo stage 3 research, assessing the efficacy and safety of its direct candidate Advert109 for managing obstructive sleep apnea (OSA). Advertisement109, a probable very first oral … [Read more...]
LivaNova Concludes Enrollment in OSA Neurostimulator Trial
Summary: LivaNova announces completion of enrollment in the OSPREY trial for its aura6000 System, an implantable neurostimulator designed to address moderate to severe obstructive sleep apnea. The system, already CE marked, aims to maintain upper airway muscle tone, reducing or … [Read more...]
Zevra to Present Data from KP1077 Phase 2 Trial in IH at SLEEP
Summary: At Slumber 2024, Zevra Therapeutics will existing the whole information from the KP1077 section 2 trial for idiopathic hypersomnia, signaling potential progress into stage 3 trials. A shareholder letter from CEO Neil McFarlane underscores this milestone, alongside … [Read more...]
FDA OKs Phase 1 Trial of Narcolepsy Drug Candidate ORX750
Summary: Centessa Prescription drugs has received Food and drug administration authorization to commence a section 1 demo of ORX750, an investigational oral therapy aimed at narcolepsy and other slumber-wake conditions. ORX750, a selective orexin receptor 2 agonist, addresses the … [Read more...]
Incannex CEO: ‘Remarkable’ Results Drive Sleep Apnea Drug Trial
Summary: Incannex Health care Inc furnished an update on its stage 2/3 trials of IHL-42X, its drug candidate becoming formulated for the procedure of obstructive rest apnea (OSA), detailing preparation throughout 25 US web sites with growth plans into Europe. This proprietary … [Read more...]
AXS-12 Reduces Narcolepsy Symptoms in Phase 3 Trial
Summary: In the SYMPHONY stage 3 trial, Axsome Therapeutics’ AXS-12 considerably lowered weekly cataplexy assaults and improved indications of narcolepsy, which include extreme daytime sleepiness, cognitive operate, and over-all ailment severity, when compared to placebo. The … [Read more...]
Evie Ring Surpasses FDA Accuracy Standards in Latest Trial
Movano Health has completed another hypoxia trial yielding new blood oxygen saturation (SpO2) data that show the accuracy of its Evie Ring pulse oximeter exceeds the US Food and Drug Administration (FDA) guidelines. The Evie Ring entered commercial production in late 2023 as a … [Read more...]